COPENHAGEN, June 23 (Reuters) - Novo Nordisk said on Monday it would halt its collaboration with Hims & Hers Health over the sale of weight loss drugs.
The two companies had announced a collaboration in April for Hims & Hers to sell Novo's blockbuster Wegovy weight loss drug through a bundled offering on the telehealth company's platform.
Novo Nordisk said in a statement on Monday that direct access to Wegovy would no longer be available to Hims & Hers Health via the NovoCare Pharmacy.
Hims & Hers shares plunged 18% on the news.
Novo Nordisk shares dropped 5.6% in premarket.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。